Products
Abagovomab Biosimilar Anti-Idiotype Antibody (CA125 Mimic) for Research
Pre-Made Abagovomab biosimilar, Whole Mab: Anti-CA125/MUC16 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Abagovomab is a mouse anti-idiotype monoclonal antibody whose variable epitope mirrors a tumour antigen (CA-125) highly expressed in the epithelial ovarian cancer. Abagovomab does not bind directly to CA-125, but it works as a "surrogate" antigen, enabling the immune system to identify and attack tumour cells displaying the CA-125 protein. Through this, it is hoped that the body's immune system may be able to combat any remaining individual tumour cells and thus prevent recurrence of the disease.
Order Information
| Catalog No. | Package | List Price(In USD) | Discount off | Discount Price |
|---|---|---|---|---|
| GMP-Bios-ab-001-1mg | 1mg | 3090 |
Size： 1mg | 10mg | 100mg
Product Details
| Products Name (INN Index) | Pre-Made Abagovomab biosimilar, Whole Mab: Anti-CA125/MUC16 therapeutic antibody |
| INN Name | Abagovomab |
| Target | MUC16 |
| Format | Whole mAb |
| Derivation | Mouse |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-III |
| Est. Status | Discontinued |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2006 |
| Year Recommended | 2007 |
| Companies | Menarini |
| Conditions Approved | na |
| Conditions Active | na |
| Conditions Discontinued | Ovarian cancer;Pancreatic cancer |
| Development Tech | na |
About target - MUC16
1. Protein Mucin-16
2. Gene MUC16
3. Organism Homo sapiens (Human)
Function
Thought to provide a protective, lubricating barrier against particles and infectious agents at mucosal surfaces.
Miscellaneous
Antigen that is the basis for a widely used serum assay for the monitoring of patients with ovarian epithelial cancer. Due to lack of sensitivity for stage I disease and lack of specificity, it is of little value in the detection of early ovarian cancer. Due to its similarly elevated levels in some nonmalignant conditions, it is not specific enough to be used for population screening.
